#London #United Kingdom #Cumulus Neuroscience #NeuLogiq #Muse by Interaxon

Cumulus Neuroscience and Muse Collaborate to Enhance At-Home Sleep EEG for Clinical Trials

In a groundbreaking announcement, Cumulus Neuroscience, a leader in the realm of digital health, has joined forces with Muse by Interaxon to incorporate advanced sleep EEG technology into the NeuLogiq® platform. This collaboration, which aims to revolutionize the approach to neuroscience clinical trials, will be officially unveiled at the upcoming Alzheimer’s Association International Conference (AAIC) in London from July 12 to 15, 2026.

Bridging the Gap with NeuLogiq® and Muse

The integration of Muse's at-home EEG technology into the NeuLogiq® platform provides a unique solution to the challenges faced in assessing sleep disturbances in neuropsychiatric and neurodegenerative conditions. Sleep issues are common in patients with such disorders and can both signal and exacerbate disease progression. Traditionally, monitoring sleep has relied on polysomnography (PSG), a method that is often costly and burdensome for participants. In contrast, most wearable devices typically assess sleep duration through indirect measures, which can lack precision.

Muse, famed for its sophisticated yet user-friendly design, offers a direct reading of the brain’s electrical activity via an at-home EEG wearable. This allows for real-time monitoring of sleep stages—enabling researchers to capture brain signals with an impressive accuracy rate of 88-96% compared to the gold-standard PSG methods, as noted in a recent study (Lanthier et al., 2025, SLEEP Advances). This capability turns what was once an arduous in-lab process into an accessible at-home experience, thus significantly reducing the patient burden associated with clinical trials.

Addressing the Need for Objective Measures

The ability to obtain objective, longitudinal data is fundamental for the progression of central nervous system (CNS) clinical development programs. According to Tina Sampath, CEO of Cumulus, the collaboration with Muse heralds a new era of integration of multi-modal measures such as cognitive function, mood, and speech into the participant's home environment. This marks a significant shift away from reliance on subjective measures traditionally used in clinical outcomes.

Muse's CEO Jean-Michel Fournier echoed this sentiment, emphasizing the importance of a comfortable user experience. He highlighted that the Muse S Athena was specifically designed for ease of use while ensuring accurate brain readings. With over 500,000 users logging more than 16.8 million nights of sleep data, Muse's technology offers a wealth of insights and reliability that researchers can now utilize effectively in clinical trials.

Benefits for CNS Clinical Trials

The integration of Muse's expertise into the NeuLogiq platform not only enables the accurate assessment of sleep but also ensures that researchers can capture valuable data without necessitating participant visits to a lab setting. This represents a transformative step toward decentralized clinical trials, allowing for greater participant diversity and more extensive data collection. As brain health emerges as a critical component in understanding disorders like Alzheimer's disease, establishing reliable sleep metrics becomes vital for developing effective therapeutic interventions.

The work being done by Cumulus and Muse is set to change the landscape of clinical trials dramatically. Early decision-making in research—a crucial factor for patient outcomes—will become more streamlined due to the real-time data generated from the NeuLogiq platform.

Future Prospects

As the collaboration unfolds at the AAIC 2026, it is anticipated that the research community will gain exceptional insights into the capabilities of the integrated NeuLogiq sleep EEG technology. By harnessing state-of-the-art tools like Muse, Cumulus Neuroscience is paving the way for future advancements in cognitive health and neurodegenerative disease management, fostering hope for millions of patients and their families.

For more information on this exciting partnership, visit Cumulus Neuroscience.